

Press Release

**Revenue up 8% to Rs. 1595 crores in Q-2 FY24,
13% to Rs 3081 crores in H-1 FY24.**

Vadodara, November 7th, 2023

Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30th September, 2023.

Financial Highlights

- Net Sales grew 8% to Rs.1595 crores for the quarter.
- Net Profit for the quarter at Rs.137 crores.
- Net Sales grew 13% to Rs.3081 crores for the H-1.
- Net Profit for H-1 at Rs.257 crores.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said “Despite the challenges of a muted demand in the Antibiotic and respiratory market, it was a satisfactory quarter, backed with a strong performance by our specialty and animal healthcare portfolio. We are confident of returning to an industry beating growth moving forward”.

Operational Highlights

India Branded Business

- India Branded Business at INR 577 crores witnessed growth of 5% in Q2FY24 against IPM growth of 7%.
- Specialty therapies recorded growth of 10%* vis a vis industry growth of 9%*.
- Performed relatively better than the market in Antibiotic and Respiratory segments. Underlying factors remain strong despite muted demand in acute market for the quarter due to weak season.
- Animal Health business recorded growth of 32% over PY Q2.

*IQVIA Qtr September' 23

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “It was a satisfactory quarter led by growth in all the verticals of the company, in particular Ex-US which grew by 17% and the API business outperformed with a 10% growth during the quarter”

Operational Highlights

International Business

- US Generics at Rs. 444 crores up by 6% on YoY basis and by 14% on QoQ basis
- Ex-US International Formulations grew 17% to Rs. 252 Crores in the quarter.
- We have regular exports now from both general injectable and oncology plants.
- 6 ANDA approvals received during the quarter; 190 Cumulative ANDA approvals.
- 2 ANDA filings during the quarter; Cumulative ANDA filings at 252.

API Business

- API business grew 10% at Rs. 322 crores in the quarter.
- 132 cumulative DMF Filings.

The summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q2 FY24	Q2 FY23	% Change	H-1 FY24	H-1 FY23	% Change
Formulation						
India	577	549	5%	1101	1029	7%
USA	444	418	6%	834	785	6%
Ex- US	252	215	17%	518	396	31%
API	322	294	10%	628	527	19%
Total	1595	1475	8%	3081	2737	13%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and

markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 022- 66953681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 6637630 Email: mitanshu.shah@alembic.co.in
--	---